A Phase 1, Open-Label, Multicentre, Non-Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD4573, a Potent and Selective CDK9 Inhibitor, in Subjects With Relapsed or Refractory Haematological Malignancies
AZD4573, a selective CDK9 inhibitor developed by AstraZeneca, targets relapsed or refractory hematological malignancies, including various forms of leukemia and lymphoma. The asset is positioned in a competitive landscape where CDK inhibitors are gaining traction due to their potential to modulate transcriptional regulation in cancer cells. The market for hematological malignancies is significant, with increasing incidence rates and a growing demand for novel therapies. AstraZeneca's investment in this asset reflects a strategic focus on expanding its oncology portfolio, particularly in areas with high unmet medical needs. The successful outcomes from this trial could enhance AstraZeneca's market position and provide leverage in negotiations with potential partners or acquirers.
Indication: Relapsed or Refractory Haematological Malignancies Including
Modality: small molecule
Target: CDK9 (Cyclin-Dependent Kinase 9)
Sponsor: AstraZeneca
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CDK9 (Cyclin-Dependent Kinase 9)
View original source fields
Condition raw: Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, High Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Richter's Syndrome, B-cell Non-Hodgkin Lymphoma, T-cell Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Multiple Myeloma
Condition normalized: Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, High Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Richter's Syndrome, B-cell Non-Hodgkin Lymphoma, T-cell Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Multiple Myeloma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: CDK9 (Cyclin-Dependent Kinase 9)
Target normalized: CDK9 (Cyclin-Dependent Kinase 9)